Fundamental Data for HITK

Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company''s Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.

# Employees: 375

Address: 369 Bayview Avenue,Amityville,NY,USA

Phone: 631 789-8228

Fax: 631 789-8429

Website: www.hitechpharm.com

Email:

Sector: Medical

Industry: MED-GENERIC DRG

Executive Officers

David S. Seltzer (Chmn.; Presi.; C.E.O.; Treas.; Sec.; Dir.)

Bernard Seltzer (Chmn. Emritus)

William Peters (V.P. C.F.O.)

Margaret Santorufo (V.P. Contro.)

Christopher LoSardo (V.P. Corp. Devept.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 7/31/2009

Next Earnings Date(Expected): 12/8/2009

Mean EPS (Next Qtr): $0.22

Mean EPS (Year): $1.42

Mean Estimate(Long Term): $20.00

P/E Ratio(Based on EPS estimate): 13.360

Number of Estimates: 1

Shares Performance

Period	HITK	Compare to S&P
YTD	242.42 %	183.37 %
4 Weeks	4.00 %	-1.27 %
12 Weeks	20.14 %	11.87 %

Shares Information

Analyst Coverage: Y

Avg Volume: 204320

Shares Outstanding: 11M

Market Cap: $0.22B

52 Week High: $25.38

52 Week Low: $3.49

P/E Ratio: 14.700

PEG Ratio: 0.670

Split: On 1/12/2006 HITK split by factor of 1.500

Earnings Performance

EPS Growth in Last Quarter: 48.78 %

EPS Growth in Last Year: 458.82 %

Sales Growth in Last Quarter: 13.47 %

Sales Growth in Last Quarter: 175.31 %

Financials

Qtr Book Value: $2.24

Cash Flow/Share: $16.59

Change in Payout Ratio: -0.010

Price/Sales: -0.010